Pharmacyte Biotech, Inc. (PMCB) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated April 24, 2025, reports the results of Pharmacyte Biotech, Inc.'s annual meeting of stockholders held on the same date. The meeting was conducted via live webcast to address matters for the fiscal year ended April 30, 2025. The company is incorporated in Nevada and trades on The Nasdaq Stock Market LLC under the symbol PMCB.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance data.
Material Changes and Voting Results
A quorum was established with 3,222,988 shares represented, approximately 46.92% of outstanding shares entitled to vote. Stockholders voted on three proposals:
- Proposal 1: Election of Directors. All five nominees were elected to serve until the 2026 annual meeting.
- Joshua N. Silverman: 957,479 For; 272,278 Withheld.
- Jonathan L. Schechter: 871,061 For; 358,696 Withheld.
- Michael M. Abecassis: 1,143,789 For; 85,968 Withheld.
- Robert Weinstein: 698,683 For; 531,074 Withheld.
- Wayne R. Walker: 863,701 For; 366,056 Withheld.
- Proposal 2: Ratification of Independent Auditor. The selection of CBIZ CPAs P.C. was ratified with 3,123,042 votes For, 72,371 Against, and 27,575 Abstain.
- Proposal 3: Executive Compensation. The non-binding advisory vote on executive compensation passed with 1,094,399 votes For, 113,815 Against, and 21,543 Abstain. There were no non-votes recorded for this proposal.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the full text of the definitive proxy statement filed on March 10, 2025, for detailed descriptions of the proposals and director biographies.
- Confirm the company's financial status and liquidity position through the most recent 10-K or 10-Q filings, as this 8-K contains no financial data.
- Note that Joshua N. Silverman is currently serving as Interim Chief Executive Officer and Interim President.
- Review the specific reasons for the "Withheld" votes on director elections, particularly for Robert Weinstein, who received the highest number of withheld votes (531,074).